

27th January, 2020

The Dy. General Manager (Listing Dept.)
BSE Limited.,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Presentation to analysts on unaudited Consolidated Financial Results for the quarter and nine months ended 31st December, 2019

The presentation on unaudited Consolidated Financial Results for the quarter and nine months ended 31st December, 2019 to be made to analysts is enclosed for your records.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL
VP (LEGAL) & COMPANY SECRETARY

Encl.: As above



Q3 FY 2019-20

Revenues: Summary



Revenue: Summary

Revenues (Rs crores)	Q3 FY20	Q3 FY19	Gr%	9M FY20	9M FY19	Gr%
India	871	832	5%	2,677	2,477	8%
United States	381	490	-22%	1,138	1,217	-6%
Germany	219	267	-18%	731	770	-5%
Brazil	189	168	12%	519	484	7%
Other countries	195	174	12%	566	504	12%
Others (Inc. CRAMS)	110	120	-8%	362	365	-1%
Total	1,966	2,051	-4%	5,993	5,817	3%

